Earnshaw SR, McDade CL, Graham CN, Spears J, Kessler C. Economic comparison of treating hemophilia patients who have developed inhibitors via immune tolerance induction versus prophylaxis and on-demand treatment with bypassing agents. Poster presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition; December 2013. New Orleans, LA. [abstract] Blood. 2013 Nov 15; 122(21):422. doi: 10.1182/blood.V122.21.422.422
Pignone M, Earnshaw S, McDade C, Pletcher MJ. Effect of including cancer mortality on the cost-effectiveness of aspirin for primary prevention in men. J Gen Intern Med. 2013 Oct;28(11):1483-91.
Wilson MR, Gutierrez B, Offord S, Zhao C, Beillat M, Eramo A, Earnshaw SR. Total healthcare cost-offset associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia. Poster presented at the US Psychiatric & Mental Health Congress; September 2013.
Earnshaw SR, Brogan AP, McDade CL. Model-based cost-effectiveness analyses for prostate cancer chemoprevention : a review and summary of challenges. Pharmacoeconomics. 2013 Apr 1;31(4):289-304.
Earnshaw SR, Brogan AJ. Markov model toolkit: concepts, assumptions and examples. Presented at the 2013 ISPOR Distance Learning Program; April 2013.
Barnes R, Earnshaw SR, Herbrecht R, Morrissey O, Slavin M, Bow E, McDade CL. Economic comparison of empirical versus diagnostic-driven strategies for immunocompromised patients with suspected fungal infection. Poster presented at the 23rd European Congress of Clinical Microbiology and Infectious Diseases; April 2013.